MONOGRAPH

Sodium Bicarbonate

Scope (Staff):	Medical, Pharmacy, Nursing, Anaesthetic Technicians
Scope (Area):	All Clinical Areas

Child Safe Organisation Statement of Commitment

CAHS commits to being a child safe organisation by applying the National Principles for Child Safe Organisations. This is a commitment to a strong culture supported by robust policies and procedures to reduce the likelihood of harm to children and young people.

This document should be read in conjunction with this **DISCLAIMER**



QUICKLINKS						
<u>Dosage/Dosage</u> <u>Adjustments</u>	<u>Administration</u>	Compatibility	Monitoring			

DRUG CLASS

Electrolyte.¹

Sodium bicarbonate is a High Risk Medicine.

INDICATIONS AND RESTRICTIONS

- Acute metabolic acidosis.²
- Hyperkalaemia.³
- Chronic acidosis (e.g. renal tubular acidosis, chronic kidney disease).⁴
- Cardiac arrest (prolonged, or in presence of hyperkalaemia or sodium channel blocker toxicity).²
- Ventricular dysrhythmias due to tricyclic antidepressant poisoning.³

CONTRAINDICATIONS 3, 4

- Hypersensitivity to sodium bicarbonate or any component of the formulation.
- Metabolic or respiratory alkalosis.

PRECAUTIONS 2, 3

- Pre-existing respiratory acidosis may worsen hypercapnia.
- Pre-existing hypernatraemia, hypocalcaemia or hypokalaemia.
- Salt-losing nephropathy increased risk of milk-alkali syndrome.
- Congestive heart failure.

FORMULATIONS

Listed below are products available at PCH, other formulations may be available, check with pharmacy if required:

- Sodium bicarbonate 8.4% 1 mmol/mL (84 mg/mL) oral liquid.
- Sodium bicarbonate 10 mmol (840 mg) oral capsule.
- Sodium bicarbonate 8.4% 1 mmol/mL (84 mg/mL) vial.

Imprest location: Formulary One

DOSAGE & ADMINISTRATION, DOSAGE ADJUSTMENTS

- For oncology indications, refer to Children's Oncology Group (COG) or other oncology specific treatment protocols relevant to the patient.
- Intravenous use in patients that are admitted under the nephrology team should always be discussed with a nephrologist.

Sodium bicarbonate administration may cause hypokalaemia and hypocalcaemia.

Monitor potassium and calcium levels closely and consider supplementation if indicated.

See monitoring section.

INTRAVENOUS (All ages)

Routine administration in cardiac arrest is not recommended. May be considered in certain cases (e.g. prolonged cardiac arrest, presence of hyperkalaemia or sodium channel blocker toxicity).²

- Extravasation may result in severe tissue damage. Monitor infusion site closely.⁵
- Administration via Central Venous Access Device (CVAD) is preferred.⁶
- If peripheral administration is necessary, administer into a large peripheral vein.⁶

Intermittent IV infusion:

- ≥ 4 weeks: 1 mmol/kg/dose (maximum 50 mmol).²
 - Repeat doses between 0.5 1 mmol/kg may be indicated, guided by individual patient's acid-base balance.²
- Higher doses of up to 2 mmol/kg/dose (maximum 100 mmol) may be indicated for treatment of salicylate or sodium channel blocker toxicity.^{3, 10}
 - Repeat doses should be guided by individual patient's acid-base balance²
 - Maximum cumulative dose: 6 mmol/kg (maximum 600 mmol)¹⁰
 - Seek urgent clinical toxicology advice if not responding to maximum dose¹⁰

Administration

- Non-urgent correction:
 - o Dilute to 0.2 mmol/mL (CVAD administration) or 0.1 mmol/mL (peripheral administration).
 - o ≥ 4 weeks: Give over 4 8 hours, to reduce the risk of intracranial haemorrhage. 1, 5, 6
 - Maximum infusion rate: 1 mmol/kg/hour^{1, 5, 6}
- IV administration in emergency situations:
 - o Preferably infuse over 30 minutes (maximum rate 10 mmol/minute)^{5, 6}
 - May be administered as an IV injection over 1 2 minutes in life-threatening situations under the direction of a consultant.¹¹
 - o Patients < 2 years Dilute to 0.5 mmol/mL.^{5, 6}
 - o Patients 2 years and above May be administered undiluted^{5, 6}

Continuous IV infusion:

- Initially 0.1 1 mmol/kg/hour, titrate to target acid-base balance.⁸
- Start at lower rate if intermittent (stat dose) IV infusion has been given prior to commencing.

Dilution:

Standard (CVAD or peripheral)	10 mmol in 100 mL (0.1 mmol/mL) Administer using large volume pump.	
Fluid restricted (CVAD only)	50 mmol in 50 mL (1 mmol/mL undiluted) Administer using syringe driver.	

Renal impairment: Monitor for sodium retention.²

Hepatic impairment: Use with caution, particularly in presence of oedema or sodium retention.²

ENTERAL

Refer to Clinical Pharmacology for indication specific dosing.

Sodium bicarbonate may significantly affect absorption, elimination or stability of certain medications (e.g. flecainide, itraconazole). Refer to PCH approved references or contact a pharmacist for advice.

COMPATIBILITY (LIST IS NOT EXHAUSTIVE)

Compatible fluids:

Glucose 5% (preferred diluent*), glucose 10%, sodium chloride 0.9%, glucose in sodium chloride solution, sodium chloride 0.45%.⁵

*Dilution with sodium chloride 0.9% increases sodium concentration.

Compatible at Y-site:

Aciclovir, cefazolin, ceftaroline, ceftazidime, ceftriaxone, ciclosporin, clindamycin, dexamethasone, esmolol, fentanyl, fluconazole, furosemide, heparin sodium, hydrocortisone sodium succinate, methylprednisolone sodium succinate.⁵

Only commonly used drugs are listed below. This is not a complete list of incompatible drugs. Compatibilities of IV drugs must be checked when two or more drugs are given concurrently.

INCOMPATIBLE drugs:

Calcium or magnesium containing solutions/drugs (including Hartmann's or Ringer's solution), adrenaline, amiodarone, amoxicillin, atracurium, caspofungin, dobutamine, dopamine, hydromorphone, isoprenaline, ketamine, labetalol, midazolam, noradrenaline, ondansetron, promethazine, suxamethonium, vancomycin.⁵

MONITORING

- Continuous ECG monitoring⁹ must be performed in patients receiving IV sodium bicarbonate infusion for correction of metabolic acidosis in presence or at high risk of other electrolyte disturbances (e.g. in patients with renal tubular acidosis).⁸
- Serial ECGs should be performed until ECG abnormalities are stabilised.
- Acid-base balance, electrolytes (bicarbonate, sodium, potassium and calcium)^{4,6} monitoring intervals to be determined by the treating team depending on individual patient factors.

ADVERSE EFFECTS

Hypernatraemia, hypokalaemia, fluid retention/overload, metabolic alkalosis.³

INTERACTIONS

This medication may interact with other medications; consult PCH approved references (e.g. Clinical Pharmacology), a clinical pharmacist or PCH Medicines Information Service on extension 63546 for more information.

Please note: The information contained in this guideline is to assist with the preparation and administration of **sodium bicarbonate. Any variations to the doses recommended should be clarified with the prescriber prior to administration**

References

- 1. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists., Pharmaceutical Society of Australia., The Royal Australian College of General Practitioners. Australian medicines handbook, 2024. Adelaide SA: Australian Medicines Handbook;
- 2. Sodium bicarbonate: drug information. Lexicomp; 2024 [Available from: <a href="https://www-uptodate-com.pklibresources.health.wa.gov.au/contents/sodium-bicarbonate-drug-information?sectionName=Pediatric&topicId=9928&search=sodium%20bicarbonate&usage_type=pa_nel&anchor=F221628&source=panel_search_result&selectedTitle=1%7E148&showDrugLabel=true&kp_tab=drug_general&display_rank=1#F51893993.
- 3. Clinical Pharmacology. 2024 [Available from: https://www-clinicalkey-com.pklibresources.health.wa.gov.au/pharmacology/.
- 4. British National Formulary for Children. BMJ Group,

Royal Pharmaceutical Society of Great Britain; 2024 [Available from: https://www-medicinescomplete-com.pklibresources.health.wa.gov.au/mc/bnfc/current/.

- 5. Burridge N, Collard N, Symons K, Society of Hospital Pharmacists of Australia. Australian injectable drugs handbook. Eighth edition. ed. Collingwood, Vic.: The Society of Hospital Pharmacist of Australia; 2024 [cited. Available from: http://aidh.hcn.com.au.pklibresources.health.wa.gov.au/browse/about_aidh.
- 6. Plover C. Paediatric injectable guidelines, 2021. Flemington, Vic: The Royal Children's Hospital;
- 7. Pediatric injectable drugs (the teddy bear book). MD: American Society of Health-System Pharmacists, Inc; 2024 [cited. Available from: Medicine Complete. Available from: https://www-medicinescomplete-com.pklibresources.health.wa.gov.au/#/browse/pid/drugs.
- 8. Erickson S. Sodium bicarbonate continuous infusion [Email]. 2024Oct 18.
- 9. PCH Safety and Quality. Sodium bicarbonate monitoring recommendations. 2024.
- 10. Therapeutic Guidelines. Tricyclic antidepressant (TCA) poisoning: Treatment for TCA poisoning. Therapeutic Guidelines Limited. 2023. [Online]. Accessed March, 31 2025. https://tgldcdp-tg-org-au.pklibresources.health.wa.gov.au/viewTopic?etgAccess=true&guidelinePage=Toxicology%20and %20Toxinology&topicfile=toxicology-TCA
- 11. Toxinz. Tricyclic Antidepressants: Antidote(s). National Poisions Centre New Zealand. 2025. [Online]. Accessed March, 31 2025. https://www-toxinz-com.pklibresources.health.wa.gov.au/specifications/tricyclic-antidepressants/?&name=Tricyclic%20Antidepressants#492097-es-cvs-bcd-head-3bm-0-7

This document can be made available in alternative formats on request for a person with a disability.

File Path:	W:\Safety & Quality\CAHS\CLOVERS MEDICAL Pharmacy\Procedures Protocols and Guidelines\Medication Monographs_Word\PCH.MED.Sodium Bicarbonate.docx		
Document Owner:	Chief Pharmacist		
Reviewer / Team:	PCC HoD, PCC CNS, ED HoD, Senior Pharmacist, Nephrologist		
Date First Issued:	October 2024	Last Reviewed:	Oct 2025
Amendment Dates:	May 2025, Oct 2025	Next Review Date:	Oct 2027
Approved by:	PCHN Medication Safety Committee	Date:	Oct 2025
Endorsed by:	CAHS Drug & Therapeutics Committee	Date:	Nov 2025
Standards Applicable:	NSQHS Standards: NSMHS: N/A Child Safe Standards: N/A		

Printed or personally saved electronic copies of this document are considered uncontrolled



Healthy kids, healthy communities

Compassion

Excellence Collaboration Accountability Equity

Neonatology | Community Health | Mental Health | Perth Children's Hospital